SCHEMBL5136223

SCHEMBL5136223

CCCCn1c(CN(CCC(C)C)Cc2ccc(N(C)C)cc2)cnc1-c1cccc(F)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
ALDH1A1 P00352 1/20 0.33
TP53 P04637 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33
MAPK1 P28482 1/20 0.33
MCL1 Q07820 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
TLR7 Q9NYK1 4/20 0.32
CHRNE Q04844 1/20 0.32
GRIN1 Q05586 1/20 0.32
GRIN2B Q13224 1/20 0.32
CCR3 P51677 1/20 0.31
ICMT O60725 1/20 0.31
GCGR P47871 1/20 0.31
TLR8 Q9NR97 1/20 0.31
LTB4R2 Q9NPC1 2/20 0.31
ADORA3 P0DMS8 1/20 0.30
ADORA2B P29275 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5137056 0.92 MEN1 (0.40) MEN1KMT2AALDH1A1TP53MAPT
SCHEMBL5135510 0.91 MEN1 (0.40) MEN1KMT2ACCR3ICMTGCGR
SCHEMBL5135038 0.91 MEN1 (0.40) MEN1KMT2ACCR3ICMTGCGR
SCHEMBL5135751 0.91 MEN1 (0.39) MEN1KMT2AICMTGCGRTLR8
SCHEMBL5075147 0.89 TSHR (0.39) MEN1KMT2AALDH1A1TP53GAA
SCHEMBL5135066 0.89 MEN1 (0.38) MEN1KMT2AICMTGCGRTLR8
SCHEMBL5135884 0.89 MEN1 (0.38) MEN1KMT2ATLR7CCR3ICMT
SCHEMBL5136012 0.89 MEN1 (0.39) MEN1KMT2ATLR7ICMTGCGR
SCHEMBL14415668 0.89 MEN1 (0.38) MEN1KMT2AALDH1A1TP53GAA
SCHEMBL5137581 0.88 MEN1 (0.38) MEN1KMT2AALDH1A1MAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed